| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fb397b8766d6ece0994c5fc06edd54f3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2a819eda0adf22936a52362eeebb9fb4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4bcfd823805ddc7d9211b319680ff16a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3d3cf0d22af83467f15d431b1ca5b198
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ca115a917d50ea01e35a22849756290b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_724ca5db1a04ad55fcbeb631553fe0ea |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2500-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-4706 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7105
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P39-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7105
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-425 |
| filingDate |
2009-11-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2016-06-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9bb6bde5d788523d35f1a62a528c426b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_043c1b527842737cf7a2ec5730813b30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4a10766f61d9f8c17872c936c252a87a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b5236909bb450445087ad203381ed91f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_abfc99007d5180801d956fe2a0c3542a |
| publicationDate |
2016-06-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-9358249-B2 |
| titleOfInvention |
Use of Pateamine A for the treatment of age-related muscle wasting |
| abstract |
In certain embodiments this invention pertains to the discovery that inhibition of the expression and/or activity of eukaryotic initiation factor 4A (eIF4A) inhibits the aging process. Accordingly, in certain embodiments, methods are provided for inhibiting/slowing aging. The methods typically involve administering to a mammal an agent that inhibits the expression and/or activity of eukaryotic initiation factor 4A (eIF4A) in an amount sufficient to inhibit expression or activity of EIF4A, where the agent is not resveratrol. |
| priorityDate |
2008-11-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |